Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 6-12~* Previously healthy~* Attending physician concludes that the patient would benefit from administration of an anxiolysis medication prior to a minor procedure~Exclusion Criteria:~* Moderate to severe asthma or other chronic lung disease~* Co-morbid conditions including cerebral palsy, developmental delay, or other chronic illness deemed by the Attending physician to be unsafe to receive anxiolysis with Versed.~* Any child presenting with a life-threatening condition.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Lidocaine (Type: EXPERIMENTAL): Patient to receive 4% lidocaine intranasally prior to midazolam
- Intranasal 0.9% saline (Type: PLACEBO_COMPARATOR): Patient to receive 0.9% Saline intranasally prior to midazolam

Based on this trial design, predict the completion outcome and termination type (if applicable).